Gabather AB (publ) (GABA) - Net Assets
Based on the latest financial reports, Gabather AB (publ) (GABA) has net assets worth Skr2.82 Million SEK (≈ $303.48K USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr7.01 Million ≈ $754.93K USD) and total liabilities (Skr4.20 Million ≈ $451.45K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GABA tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr2.82 Million |
| % of Total Assets | 40.2% |
| Annual Growth Rate | N/A |
| 5-Year Change | -107.87% |
| 10-Year Change | -102.6% |
| Growth Volatility | 304.6 |
Gabather AB (publ) - Net Assets Trend (2014–2025)
This chart illustrates how Gabather AB (publ)'s net assets have evolved over time, based on quarterly financial data. See GABA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Gabather AB (publ) (2014–2025)
The table below shows the annual net assets of Gabather AB (publ) from 2014 to 2025. For live valuation and market cap data, see GABA market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr-863.00K ≈ $-92.87K |
+79.33% |
| 2024-12-31 | Skr-4.17 Million ≈ $-449.30K |
-959.05% |
| 2023-12-31 | Skr486.00K ≈ $52.30K |
-85.86% |
| 2022-12-31 | Skr3.44 Million ≈ $369.98K |
-68.64% |
| 2021-12-31 | Skr10.96 Million ≈ $1.18 Million |
-62.00% |
| 2020-12-31 | Skr28.85 Million ≈ $3.10 Million |
-33.82% |
| 2019-12-31 | Skr43.59 Million ≈ $4.69 Million |
+174.71% |
| 2018-12-31 | Skr15.87 Million ≈ $1.71 Million |
-65.32% |
| 2017-12-31 | Skr45.76 Million ≈ $4.92 Million |
+37.89% |
| 2016-12-31 | Skr33.19 Million ≈ $3.57 Million |
+159.56% |
| 2015-12-31 | Skr12.79 Million ≈ $1.38 Million |
+48.06% |
| 2014-12-31 | Skr8.63 Million ≈ $929.25K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Gabather AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11858877900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr4.69 Million | % |
| Other Comprehensive Income | Skr880.00K | % |
| Other Components | Skr113.88 Million | % |
| Total Equity | Skr-863.00K | 100.00% |
Gabather AB (publ) Competitors by Market Cap
The table below lists competitors of Gabather AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bonyf NV
PA:MLBON
|
$2.48 Million |
|
Invion Ltd
AU:IVX
|
$2.48 Million |
|
Aethlon Medical Inc
NASDAQ:AEMD
|
$2.49 Million |
|
OurLiving AB
ST:OURLIV
|
$2.49 Million |
|
Thrive Tribe Technologies Ltd
AU:1TT
|
$2.48 Million |
|
NAYA Biosciences, Inc
NASDAQ:NAYA
|
$2.48 Million |
|
China Pharma Holdings Inc
NYSE MKT:CPHI
|
$2.48 Million |
|
PolyPlank publ AB
ST:POLY
|
$2.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gabather AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -4,175,000 to -863,000, a change of 3,312,000.
- Net loss of 4,652,000 reduced equity.
- Share repurchases of 9,489,000 reduced equity.
- New share issuances of 12,780,000 increased equity.
- Other comprehensive income increased equity by 880,000.
- Other factors increased equity by 3,793,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-4.65 Million | -539.05% |
| Share Repurchases | Skr9.49 Million | -1099.54% |
| Share Issuances | Skr12.78 Million | +1480.88% |
| Other Comprehensive Income | Skr880.00K | +101.97% |
| Other Changes | Skr3.79 Million | +439.51% |
| Total Change | Skr- | % |
Book Value vs Market Value Analysis
This analysis compares Gabather AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr3.61 | Skr0.04 | x |
| 2015-12-31 | Skr4.29 | Skr0.04 | x |
| 2016-12-31 | Skr9.08 | Skr0.04 | x |
| 2017-12-31 | Skr12.38 | Skr0.04 | x |
| 2018-12-31 | Skr3.08 | Skr0.04 | x |
| 2019-12-31 | Skr6.77 | Skr0.04 | x |
| 2020-12-31 | Skr2.08 | Skr0.04 | x |
| 2021-12-31 | Skr0.82 | Skr0.04 | x |
| 2022-12-31 | Skr0.25 | Skr0.04 | x |
| 2023-12-31 | Skr0.03 | Skr0.04 | x |
| 2024-12-31 | Skr-0.20 | Skr0.04 | x |
| 2025-12-31 | Skr0.00 | Skr0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gabather AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-223.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -29.95% | 0.00% | 0.00x | 1.06x | Skr-3.45 Million |
| 2015 | -46.65% | 0.00% | 0.00x | 1.06x | Skr-7.24 Million |
| 2016 | -23.79% | -1657.49% | 0.01x | 1.05x | Skr-11.21 Million |
| 2017 | -21.72% | -330.04% | 0.06x | 1.05x | Skr-14.51 Million |
| 2018 | -128.01% | -44218.55% | 0.00x | 1.14x | Skr-21.90 Million |
| 2019 | -32.76% | -3859884.05% | 0.00x | 1.06x | Skr-18.64 Million |
| 2020 | -53.56% | 0.00% | 0.00x | 1.15x | Skr-17.74 Million |
| 2021 | -155.04% | 0.00% | 0.00x | 1.40x | Skr-18.10 Million |
| 2022 | -248.55% | 0.00% | 0.00x | 1.96x | Skr-8.89 Million |
| 2023 | -1941.77% | 0.00% | 0.00x | 15.15x | Skr-9.49 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | Skr-7.34 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | Skr-4.57 Million |
Industry Comparison
This section compares Gabather AB (publ)'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $253,411,537
- Average return on equity (ROE) among peers: -211.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gabather AB (publ) (GABA) | Skr2.82 Million | -29.95% | 1.49x | $2.48 Million |
| BioGaia AB (publ) (BIOG-B) | $132.42 Million | 27.28% | 0.17x | $1.25 Billion |
| Enzymatica publ AB (ENZY) | $124.97 Million | -36.32% | 0.26x | $65.83 Million |
| Enorama Pharma AB (ERMA) | $1.78 Million | -1345.02% | 22.02x | $2.69 Million |
| Klaria Pharma Holding AB (KLAR) | $69.42 Million | -77.12% | 0.70x | $20.99 Million |
| Moberg Pharma AB (publ) (MOB) | $15.23 Million | -232.05% | 0.48x | $46.74 Million |
| Nanexa AB (NANEXA) | $101.53 Million | -11.22% | 0.36x | $77.75 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $68.77 Million | -21.33% | 0.26x | $6.28 Million |
| Orexo AB (ORX) | $58.90 Million | -217.83% | 12.35x | $79.38 Million |
| Swedish Orphan Biovitrum AB (publ) (SOBI) | $1.71 Billion | 10.32% | 0.60x | $16.38 Billion |
About Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more